WALLINGFORD, Conn., Oct. 16, 2013 /PRNewswire/ -- CyVek, Inc., an innovator in multi-analyte immunoassay technology, announced today that it has appointed Bill Dubiel to the role of Chief Commercial Officer. In this role, Mr. Dubiel will lead CyVek's global commercialization efforts for the new CyPlex™ System. Mr. Dubiel will report to CyVek's President and CEO, Per Hellsund.
Per Hellsund, CyVek founder, President and CEO commented, "We are very pleased to have Bill join our leadership team. His breadth of experience in the industry and entrepreneurial spirit will ensure we are well prepared for commercial success. His immediate focus will be on building a customer-centric sales, marketing and service organization and putting the systems and processes in place to commercialize our novel technology."
Mr. Dubiel has more than 25 years of experience in the medical device industry and brings extensive commercial knowledge to the team. He joins CyVek, Inc. from Roche Tissue Diagnostics, where he was Vice President of Sales. Prior to that, he held senior level positions at Bayer Healthcare, Chiron and Ciba-Corning Diagnostics. He has successfully led sales, marketing and service organizations and has been a part of 3 major product launches in the clinical market and most recently led a successful system launch in the life science segment.
"I am excited to join the CyVek team. CyVek has developed a unique immunoassay system that improves quality, enhances productivity and controls the cost of producing diagnostic results. These are the key ingredients of success in the healthcare model today and I am fortunate to play a role in bringing this technology to customers and ultimately the patients they serve. Our approach will provide a flexible and interactive experience to the customer, one that focuses on the quality and reliability of results just like our products do," Mr. Dubiel said.
CyVek was formed in 2010 and is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led companies from start up to liquidity events.
About CyVek, Inc.
CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. CyVek's CyPlex™ is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. For more information about CyVek, please call 203-679-0395 or visit us on the web at www.cyvek.com
Contact: Bill Dubiel, 203-679-0395, email@example.com
SOURCE CyVek, Inc.